


PRODUCT: Cobimetinib

ALTERNATE NAMES: XL518; XL-518; XL 518; GDC0973; GD C0973; GDC-0973; [3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]-[3-hydroxy-3-[(2S)-piperidin-2-yl]azetidin-1-yl]methanone

CATALOG#: B1689-5, -25

AMOUNT: 5 mg, 25 mg

STRUCTURE:



MOLECULAR FORMULA: C₂₁H₂₁F₃IN₃O₂

MOLECULAR WEIGHT: 531.31

CAS NUMBER: 934660-93-2

APPEARANCE: Solid powder

SOLUBILITY: DMSO

PURITY: >98%

STORAGE: Dry, dark and at 4°C for short term (days to weeks) or at -20°C for long term. Protect from air and light.

DESCRIPTION: Cobimetinib (GDC-0973; XL518) is a potent, highly selective inhibitor of mitogen-activated protein kinase kinase (MEK1/2).

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

REFERENCES:

1. Hoeflich KP et al. Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition. *Cancer Res.* 2012 Jan 1;72(1):210-9.
2. Choo EF et al. PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts. *Cancer Chemother Pharmacol.* 2013 Jan;71(1):133-43.
3. Corazao-Rozas P et al. Mitochondrial oxidative phosphorylation controls cancer cell's life and death decisions upon exposure to MAPK inhibitors. *Oncotarget.* 2016 Feb 29. doi: 10.18632/oncotarget.7790.

RELATED PRODUCTS:

- PD184352 (Cat. No. 1585-1, 5, 25)
- EZSolution™ PD184352 (Cat. No. 1871-1)
- PD 98059 (Cat. No. 1666-5)
- EZSolution™ PD 98059 (Cat. No. 1783-5)
- SB 203580 (Cat. No. 1712-1, 5)
- EZSolution™ SB-203580 (Cat. No. 1786-1)
- U0126 (Cat. No. 1668-5)
- Sorafenib (Cat. No. 1594-25, 100)
- VX-702 (Cat. No. 1598-1, 5)

USAGE: **FOR RESEARCH USE ONLY! Not to be used in humans**